Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $13.33 Average PT from Brokerages
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target […]
More Stories
First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC) Reaches New 1-Year High – Here’s Why
First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC – Get Free Report)’s stock price reached a new 52-week high on...
Banco de Sabadell, S.A. (OTCMKTS:BNDSY) Short Interest Up 1,000.0% in December
Banco de Sabadell, S.A. (OTCMKTS:BNDSY – Get Free Report) was the recipient of a significant growth in short interest in...
Tapestry (NYSE:TPR) Hits New 1-Year High – Here’s Why
Tapestry, Inc. (NYSE:TPR – Get Free Report) hit a new 52-week high on Wednesday . The stock traded as high...
Campbell Newman Asset Management Inc. Sells 6,426 Shares of Honeywell International Inc. (NASDAQ:HON)
Campbell Newman Asset Management Inc. lowered its holdings in shares of Honeywell International Inc. (NASDAQ:HON – Free Report) by 7.1%...
Canadian Tire (TSE:CTC.A) Hits New 1-Year High – What’s Next?
Canadian Tire Co. Limited (TSE:CTC.A – Get Free Report) hit a new 52-week high during trading on Wednesday . The...
Cisco Systems (NASDAQ:CSCO) Sets New 12-Month High – Still a Buy?
Cisco Systems, Inc. (NASDAQ:CSCO – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Wednesday...